Dreavent Capital

Dreavent Capital is an active venture capital firm specializing in life sciences/biotech. It focuses on investing in early clinical-stage companies with strong proof-of-concept data and robust backing from major pharma or top-tier VCs. Its recent investments include Astrocyte Pharmaceuticals (neuroprotection for brain injuries), Aardvark Therapeutics (hyperphagia/Prader-Willi syndrome), Chimeron Bio (mRNA cancer vaccines), Elicio Therapeutics (cancer immunotherapy), Therini Bio (fibrin-targeting for neuroinflammation), Inspirna (first-in-class cancer medicines), among others. The fund’s strategy emphasizes risk mitigation by targeting de-risked assets with high innovation potential backed by large pharma partners or syndicates. Dreavent Capital focuses exclusively on life science/biotech investing at early clinical stages—especially IND through Phase II trials—with emphasis on Oncology, Neurology/CNS disorders, Immunology/Inflammation, Cardiovascular & Metabolic indications. It invests only where there are strong scientific foundations plus validation from major pharma/top-tier VC syndicates to mitigate risk. Its portfolio includes innovative therapeutics across small molecules/mAbs/mRNA/gene therapy platforms depending upon investee company pipeline—not developing drugs themselves but enabling their progress through strategic funding/support.